Kura Oncology Announces Board, Officer, and Compensation Changes
Ticker: KURA · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-changes, board-changes
Related Tickers: KURA
TL;DR
Kura Oncology reshuffled its board and exec team, with new appointments and compensation plans announced.
AI Summary
Kura Oncology, Inc. announced on June 5, 2024, a series of significant corporate changes. These include the election of new directors, the appointment of new officers, and changes to executive compensation arrangements. The company also reported on matters submitted to a vote of its security holders and filed financial statements and exhibits.
Why It Matters
Changes in board composition and executive leadership can signal shifts in company strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and governance can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors as an item of report, but does not specify the names of newly elected or departing directors in the provided text.
Were there any changes in executive officers?
Yes, the filing reports on the appointment of certain officers.
What is the nature of the changes in compensatory arrangements?
The filing states that there were changes to the compensatory arrangements of certain officers, but the specific details are not provided in this excerpt.
Were any matters put to a vote of security holders?
Yes, the filing indicates the submission of matters to a vote of security holders.
What financial statements or exhibits were filed?
The filing includes financial statements and exhibits, though the specific content is not detailed in this excerpt.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2024-06-07 16:05:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
Filing Documents
- kura-20240605.htm (8-K) — 72KB
- kura-ex99_1.htm (EX-99.1) — 395KB
- 0000950170-24-070584.txt ( ) — 643KB
- kura-20240605.xsd (EX-101.SCH) — 30KB
- kura-20240605_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, we held our Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 8, 2024, the record date for the Annual Meeting, there were 76,180,620 shares of common stock outstanding, of which 69,762,653 shares of common stock were present virtually or represented by proxy at the Annual Meeting. At the Annual Meeting, stockholders: (1) elected Troy E. Wilson, Ph.D., J.D. and Faheem Hasnain as Class I directors to hold office until our 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal ; (2) ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; (3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement; and (4) approved our Amended 2014 Plan as disclosed in the proxy statement. The following sets forth detailed information regarding the final results of the voting for the Annual Meeting (with any fractional share amounts rounded to the nearest whole number): Proposal 1. Election of Directors Name of Director Elected For Withheld Broker Non-Votes Troy E. Wilson, Ph.D., J.D. 59,332,182 7,740,382 2,690,089 Faheem Hasnain 59,745,514 7,327,050 2,690,089 Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 69,596,811 56,740 109,102 — Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 61,538,693 5,449,767 111,285 2,662,908 Proposal 4. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 53,621,818 11,993,394 1,484,533 2,662,908
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KURA ONCOLOGY, INC. Date: June 7, 2024 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer